ACUTE RENAL ALLOGRAFT REJECTION REVERSAL AGENT CLINICAL TRIALS SHOULD INCLUDE SIX-MONTH FOLLOW-UP, BIOLOGICAL RESPONSE MODIFIERS ADV. CMTE. CONCLUDES
Executive Summary
Clinical trials of agents to treat acute renal allograft rejection should include six-month follow-up data to assess the durability of response, FDA's Biological Response Modifiers Advisory Committee agreed at its Dec. 8 meeting.